Nowikiewicz Tomasz, Wnuk Paweł, Małkowski Bogdan, Kurylcio Andrzej, Kowalewski Janusz, Zegarski Wojciech
Department of Clinical Breast Cancer and Reconstructive Surgery, Oncology Center, Bydgoszcz, Poland.
Surgical Oncology Clinic, Collegium Medicum, Nicolaus Copernicus University, Oncology Center, Bydgoszcz, Poland.
Arch Med Sci. 2017 Oct;13(6):1399-1407. doi: 10.5114/aoms.2016.57677. Epub 2016 May 5.
The aim of this study was to present a new predictive tool for non-sentinel lymph node (nSLN) metastases.
One thousand five hundred eighty-three patients with early-stage breast cancer were subjected to sentinel lymph node biopsy (SLNB) between 2004 and 2012. Metastatic SLNs were found in 348 patients - the retrospective group. Selective axillary lymph node dissection (ALND) was performed in 94% of cases. Involvement of the nSLNs was identified in 32.1% of patients following ALND. The correlation between nSLN involvement and selected epidemiological data, primary tumor features and details of the diagnostic and therapeutic management was examined in metastatic SLN group. Multivariate analysis was performed using an artificial neural network to create a new nomogram. The new test was validated using the overall study population consisting of the prospective group (365 patients - SLNB between 01-07.2013).
Accuracy of the new test was calculated using area under the receiver operating characteristics curve (AUC). We obtained AUC coefficient equal to 0.87 (95% confidence interval: 0.81-0.92). Sensitivity amounted to 69%, specificity to 86%, accuracy - 80% (retrospective group) and 77%, 46%, 66% (validation group), respectively. The Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram the calculated AUC value was 0.71, for Stanford - 0.68, for Tenon - 0.67.
In the analyzed group only the MSKCC nomogram and the new model showed AUC values exceeding the expected level of 0.70. Our nomogram performs well in prospective validation on patient series. The overall assessment of clinical usefulness of this test will be possible after testing it on different patient populations.
本研究的目的是提出一种用于预测非前哨淋巴结(nSLN)转移的新工具。
2004年至2012年间,对1583例早期乳腺癌患者进行了前哨淋巴结活检(SLNB)。348例患者发现前哨淋巴结转移,为回顾性组。94%的病例进行了选择性腋窝淋巴结清扫(ALND)。ALND后32.1%的患者发现nSLN受累。在前哨淋巴结转移组中,研究了nSLN受累与选定的流行病学数据、原发性肿瘤特征以及诊断和治疗管理细节之间的相关性。使用人工神经网络进行多变量分析以创建新的列线图。使用由前瞻性组(365例患者,2013年1月至7月进行SLNB)组成的总体研究人群对新测试进行验证。
使用受试者操作特征曲线(AUC)下的面积计算新测试的准确性。我们获得的AUC系数等于0.87(95%置信区间:0.81 - 0.92)。敏感性为69%,特异性为86%,准确性在回顾性组中为80%,在验证组中分别为77%、46%、66%。纪念斯隆凯特琳癌症中心(MSKCC)列线图计算出的AUC值为0.71,斯坦福大学列线图为0.68,特农医院列线图为0.67。
在分析的组中,只有MSKCC列线图和新模型的AUC值超过了预期的0.70水平。我们的列线图在对患者系列进行前瞻性验证时表现良好。在对不同患者群体进行测试后,将有可能对该测试的临床实用性进行全面评估。